IP Library Granted Patent US 7,943,303
Granted Patent B2
US 7,943,303 · App. 11/013,260 · Granted May 17, 2011

Method for engineering strand-specific nicking endonucleases from restriction endonucleases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,303
App. No.
11/013,260
Granted
May 17, 2011
Kind
B2
Abstract

Methods are provided for engineering novel strand-specific nicking endonucleases by means of an in vivo enrichment of a plasmid library containing a randomly mutagenized restriction endonuclease gene. The plasmids contain adjacent to the gene a cleavable or nickable sequence for cleaving or nicking by the endonuclease product of the gene and a second recognition site for a second endonuclease. The plasmid library is used to transform unmodified host cells. Plasmids from the cultured transformed cells may be analyzed by an in vitro assay for nicking and the nicked plasmids pooled and used to transform host cells. The product is then pooled and the single-stranded specificity of the endonuclease is then determined. The product is either cloned after amplification or identified by use of a selectable marker.

Claims (20)

1. A method comprising:

(a) obtaining a library of plasmids, in which the individual plasmids comprise:

(i) a gene coding for a wild-type restriction endonuclease that has been randomly mutagenized, and is positioned between a promoter operably linked to the gene and a known asymmetric recognition sequence for the wild-type restriction endonuclease; and

(ii) a substrate site for nicking by a first nicking endonuclease adjacent to the asymmetric recognition sequence;

(b) transforming a first population of host cells with the library of plasmids, the first population of host cells lacking a protective methylase for the wild type restriction endonuclease;

(c) isolating the plasmids from the transformed first population of host cells, the isolated plasmids comprising supercoiled DNAs and open circular DNAs wherein the open circular DNAs contain a nick at the known asymmetric restriction sequence resulting from cleavage by a product of the randomly mutagenized restriction endonuclease gene having nicking activity, the open circular DNAs thus encoding a second nicking endonuclease gene;

(d) combining the isolated plasmids in vitro with the first nicking endonuclease so as to permit nicking of the isolated plasmids at the substrate site such that the open circular DNAs with the nick at the known asymmetric restriction sequence are linearized; and

(e) introducing the second nicking endonucleases gene into a second population of host cells premodified with a protective methylase and expressing the second nicking endonucleases gene.

2. The method according to claim 1 , wherein the randomly mutagenized restriction endonuclease genes in the library of plasmids differ from the gene encoding the wild-type restriction endonuclease by a deletion, an insertion or a substitution of one or more nucleotides of the wild-type restriction endonuclease gene.

3. The method according to claim 1 , further comprising prior to step (d): separating the open circular from the supercoiled plasmid DNA wherein in step (d), the isolated plasmids consist of the open circular DNA.

4. The method according to claim 3 , further comprising identifying whether the second nicking endonuclease is:

(i) a top strand-nicking endonuclease wherein the linearized plasmid is nicked on the bottom strand by the first endonuclease; or

(ii) a bottom strand-nicking endonuclease wherein the linearized plasmid is nicked on the top strand by the first endonucleases.

5. The method according to claim 1 , wherein the linearized DNA in (d) has a 5′ cohesive end and a 3′ cohesive end and the step of introducing comprises: annealing a DNA adaptor to the 5′ cohesive end; selecting a primer for hybridizing to the adaptor or to the 3′ cohesive end; amplifying the linearized DNA; and inserting the amplified DNA into a cloning vector such that the amplified DNA is operably linked to an expression control sequence and transformation of the cloning vector into the second population of host cells.

6. The method according to claim 1 , wherein the linearized plasmid in (d) has a first cohesive end and a second cohesive end, the step of introducing comprises ligating the first cohesive end to the second cohesive end to form a circular plasmid and transforming the circular plasmid into the second population of host cells pre-modified with the protective methylase.

7. The method according to claim 1 , wherein the linearized plasmid in (d) has a first cohesive end and a second cohesive end, the step of introducing comprises: ligating to the first and second cohesive end of the linearized plasmid, a selectable marker gene with the same two cohesive ends; to form a circular plasmid and transforming the circular plasmid into the second population of host cells pre-modified with the protective methylase.

8. The method according to claim 1 , wherein step (e) further comprises: over-expressing the second nicking endonuclease in the second population of host cells.

9. The method according to claim 1 , further comprising: identifying the one or more mutations in the gene encoding the second nicking endonuclease.

10. The method according to claim 9 , further comprising: introducing the one or more mutations into an isoschizomer or neoschizomer of the wild type restriction endonuclease by site-directed mutagenesis.

11. The method according to claim 1 , wherein the restriction endonuclease is SapI.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2004
From: XU, SHUANG-YONG; SAMUELSON, JAMES
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 016104/0790 →